<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Kawasaki Disease - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    
    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Kawasaki Disease</span>
        </nav>

        <header class="page-header">
            <h1>Kawasaki Disease</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Pediatric Condition</span>
                
                
                <span class="badge badge-mondo">
                    <a href="https://monarchinitiative.org/disease/MONDO:0012727" target="_blank">
                        MONDO:0012727
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Vasculitis</span>
                
            </div>
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">8</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
        </div>

        <!-- Subtypes -->
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Vascular Inflammation</div>
                
                <div class="item-desc">Widespread inflammation of medium-sized arteries, including coronary arteries.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (6 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/23188196" target="_blank">PMID:23188196</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Kawasaki disease (KD) is considered to be a kind of systemic vasculitis syndrome. It most frequently affects infants and young children and primarily invades medium-sized muscular arteries, including the coronary arteries."</div>
                
                
                <div class="evidence-explanation">The literature confirms that Kawasaki disease involves widespread inflammation of medium-sized arteries, including coronary arteries.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/31599798" target="_blank">PMID:31599798</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Kawasaki disease is a childhood vasculitis of unknown origin, whose major complication is the development of coronary artery aneurysms (CAA)."</div>
                
                
                <div class="evidence-explanation">The literature supports that Kawasaki disease leads to vascular inflammation and aneurysm formation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/27090101" target="_blank">PMID:27090101</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Coronary angiography showed multiple aneurysms which suggested sequelae of misdiagnosed Kawasaki disease."</div>
                
                
                <div class="evidence-explanation">The case report indicates that Kawasaki disease can lead to aneurysm formation as a result of vascular inflammation.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 3 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Immune Response Dysregulation</div>
                
                <div class="item-desc">An abnormal immune response leading to vessel wall damage and inflammation.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/34890998" target="_blank">PMID:34890998</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Increasing evidence shows that the pathogenesis of Kawasaki disease (KD) is caused by abnormal and unbalanced innate and adaptive immune responses."</div>
                
                
                <div class="evidence-explanation">The literature supports the statement that Kawasaki Disease is characterized by immune response dysregulation leading to vessel wall damage and inflammation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/30183655" target="_blank">PMID:30183655</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Kawasaki disease (KD) is a vasculitis that is part of systemic vasculitis syndrome. It affects medium-sized vessels and is characterized by hypercytokinemia."</div>
                
                
                <div class="evidence-explanation">This reference supports that KD involves immune dysregulation leading to vessel wall damage.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/30619331" target="_blank">PMID:30619331</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Others have favored an autoreactive hypothesis that KD is triggered by an antigen that shares homology with structures in the vascular wall, and molecular mimicry resulting in an immune response directed to that tissue."</div>
                
                
                <div class="evidence-explanation">This supports the notion of an abnormal immune response leading to vessel wall damage in KD.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">⬡</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph TD
    Vascular_Inflammation[&#34;Vascular Inflammation&#34;]
    Aneurysm_Formation[&#34;Aneurysm Formation&#34;]

    Vascular_Inflammation --&gt; Aneurysm_Formation

    style Vascular_Inflammation fill:#dbeafe
    style Aneurysm_Formation fill:#fef3c7</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">8</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Fever
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001945" target="_blank">
                            HP:0001945
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/30029859" target="_blank">PMID:30029859</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Fever, abdominal pain, and vomiting were the most frequent symptoms observed and typical Kawasaki disease signs and symptoms appeared after intestinal complaints in all cases."</div>
                
                
                <div class="evidence-explanation">The literature mentions fever as one of the most frequent symptoms observed in Kawasaki disease, supporting the statement that fever is a very frequent systemic diagnostic symptom of Kawasaki disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/31900257" target="_blank">PMID:31900257</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The conundrum for acute paediatricians is which clinical features best distinguish the febrile child with possible KD, needing intravenous immunoglobulin, from the many other children with febrile illnesses."</div>
                
                
                <div class="evidence-explanation">The literature highlights the challenge of distinguishing Kawasaki disease from other febrile illnesses, indicating that fever is a very frequent systemic diagnostic symptom in Kawasaki disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26631821" target="_blank">PMID:26631821</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The main symptoms were fever (100%), exanthema (98%), changes in the extremities (91%), conjunctivitis (77%), oral cavity changes (89%), cervical adenitis (55%) and cardiac abnormalities (45%)."</div>
                
                
                <div class="evidence-explanation">The literature states that fever is present in 100% of the cases, supporting the statement that fever is a very frequent systemic diagnostic symptom of Kawasaki disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Rash
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Dermatologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0000988" target="_blank">
                            HP:0000988
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26631821" target="_blank">PMID:26631821</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The main symptoms were fever (100%), exanthema (98%)..."</div>
                
                
                <div class="evidence-explanation">Exanthema, which refers to a widespread rash, was present in 98% of the adult patients with Kawasaki Disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/1440951" target="_blank">PMID:1440951</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"We describe a four-year-old girl who presented with fever, a diffuse erythematous maculopapular rash..."</div>
                
                
                <div class="evidence-explanation">The case description includes a diffuse erythematous maculopapular rash as one of the clinical features.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/33453126" target="_blank">PMID:33453126</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"All children with KD have fever accompanied by clinical signs, with four of the five classic criteria for complete KD being mucocutaneous..."</div>
                
                
                <div class="evidence-explanation">The abstract emphasizes the mucocutaneous manifestations, which include skin rashes, as critical for diagnosing Kawasaki Disease.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Conjunctivitis
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Ocular</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0000509" target="_blank">
                            HP:0000509
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Non-purulent (no pus)</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/34814144" target="_blank">PMID:34814144</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"In cross-sectional studies, KD was associated with allergic rhinitis (n = 6; OR, 1.69; 95% CI, 1.52-1.87), asthma (n = 3; OR, 1.72; 95% CI, 1.38-2.14), allergic conjunctivitis (n = 2; OR, 1.95; 95% CI, 1.68-2.27), and atopic dermatitis (n = 3; OR, 1.35; 95% CI, 1.22-1.49)."</div>
                
                
                <div class="evidence-explanation">The study shows that Kawasaki Disease is associated with allergic conjunctivitis, supporting the statement that conjunctivitis is very frequent in Kawasaki Disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32843441" target="_blank">PMID:32843441</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Both patients presented with fever lasting &gt;5 days and were found to have rash, conjunctival injection, and swollen lips."</div>
                
                
                <div class="evidence-explanation">The description of conjunctival injection in patients with Kawasaki Disease supports the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/7299613" target="_blank">PMID:7299613</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"In a prospective series, ophthalmologic examinations on 10 children with Kawasaki disease showed that eight had anterior uveitis during the acute phase of the illness."</div>
                
                
                <div class="evidence-explanation">Although the study focuses on anterior uveitis, it indicates significant ocular involvement in Kawasaki Disease, supporting the statement indirectly.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Swelling of Hands and Feet
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Musculoskeletal</span>
                    
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/1704148" target="_blank">PMID:1704148</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The six main clinical presentations of Kawasaki disease are: prolonged fever, conjunctivitis, lesions of the oral and pharyngeal mucosa, inflammatory reddening and swelling of the hands and feet, skin rash and cervical lymph node enlargement."</div>
                
                
                <div class="evidence-explanation">The literature explicitly mentions that swelling of the hands and feet is one of the six main clinical presentations of Kawasaki disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/3333141" target="_blank">PMID:3333141</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Early clinical features include fever, rash, conjunctival injection, dry reddened lips, oropharyngeal reddening, enlarged cervical nodes, and swelling and redness of hands and feet."</div>
                
                
                <div class="evidence-explanation">The literature lists swelling and redness of hands and feet as early clinical features of Kawasaki disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Peeling Skin
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Dermatologic</span>
                    
                    
                </div>
                
                <div class="item-desc">Particularly on the fingers and toes, often during the subacute phase</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/6833960" target="_blank">PMID:6833960</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The second, subacute, phase begins with a decline of the acute findings and proceeds with desquamation of rash..."</div>
                
                
                <div class="evidence-explanation">The term &#39;desquamation&#39; refers to peeling of the skin, which supports the statement that peeling skin is a frequent dermatologic manifestation of Kawasaki Disease, particularly during the subacute phase.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/3333141" target="_blank">PMID:3333141</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Peeling of skin of fingers and toes, arthralgia, and marked thrombocytosis are frequent 1-2 weeks after onset."</div>
                
                
                <div class="evidence-explanation">This reference explicitly mentions that peeling of the skin on the fingers and toes is a frequent occurrence 1-2 weeks after the onset of Kawasaki Disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/37065507" target="_blank">PMID:37065507</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Kawasaki disease&#39;s clinical manifestations range from oral skin disease to the blistering of the mucosa, symptoms involving the hands and the feet, skin disease of the palms and soles, a desquamative rash..."</div>
                
                
                <div class="evidence-explanation">The term &#39;desquamative rash&#39; indicates peeling skin, supporting the statement that this is a frequent dermatologic manifestation of Kawasaki Disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Red, Cracked Lips
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Oropharyngeal</span>
                    
                    
                </div>
                
                <div class="item-desc">Includes &#34;strawberry tongue&#34; and inflammation in the mouth and throat</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/15835487" target="_blank">PMID:15835487</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The disease can present with protean clinical manifestations which include high grade fever (for at least 5 days), rash, redness of the lips and a typical strawberry tongue, cervical lymph node enlargement (often unilateral), swelling over the hands/feet and, later a characteristic peripheral..."</div>
                
                
                <div class="evidence-explanation">The abstract mentions redness of the lips and a typical strawberry tongue as clinical manifestations of Kawasaki disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/30903929" target="_blank">PMID:30903929</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Kawasaki disease (KD) is a febrile multisystemic vasculitis of unknown etiology whose coronary prognosis is improved by early diagnosis and management. ... ENT manifestations are frequently at the forefront of KD and constitute a misleading clinical picture responsible for delayed diagnosis and..."</div>
                
                
                <div class="evidence-explanation">The study indicates that ENT (ear, nose, and throat) manifestations, which include oropharyngeal symptoms, are frequently at the forefront of KD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/1440951" target="_blank">PMID:1440951</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"We describe a four-year-old girl who presented with fever, a diffuse erythematous maculopapular rash, bilateral nonpurulent bulbar conjunctivitis, dry, red, fissured lips, a tongue with a strawberry &#39;appearance&#39;, an erythematous pharynx, indurative erythema, and edema and desquamation of the..."</div>
                
                
                <div class="evidence-explanation">The case description includes dry, red, fissured lips and a tongue with a strawberry &#39;appearance&#39;, supporting the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Coronary Artery Aneurysms
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Cardiovascular</span>
                    
                    
                </div>
                
                <div class="item-desc">Can lead to serious heart complications</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/10512599" target="_blank">PMID:10512599</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Coronary artery aneurysms or ectasia develop in approximately 15-25% of children with the disease."</div>
                
                
                <div class="evidence-explanation">The literature indicates that coronary artery aneurysms are a common complication of Kawasaki disease, occurring in 15-25% of cases, which is more frequent than &#39;occasional&#39;.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/31732547" target="_blank">PMID:31732547</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Twenty-three patients had SAAs, demonstrating an incidence of 14.2% (23 of 162) in patients who were screened at 1 month after onset. The proportion of patients with SAAs was estimated to be 2% (23 of 1148) of all patients with KD."</div>
                
                
                <div class="evidence-explanation">The incidence of coronary artery aneurysms (CAAs) in Kawasaki disease is significant, with a notable percentage of patients developing CAAs, indicating that the frequency is more than &#39;occasional&#39;.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/34651205" target="_blank">PMID:34651205</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Among the 640 KD children, most were 1-5 years old (415/640, 64.8%). Children &lt; 1 year old (31.6%) and &gt; 5 years old (28.3%) were more likely to have cardiovascular complications."</div>
                
                
                <div class="evidence-explanation">The study shows a high incidence of cardiovascular complications in children with Kawasaki disease, indicating that coronary artery aneurysms and other heart complications are not just occasional.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Aneurysm Formation
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Cardiovascular</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002617" target="_blank">
                            HP:0002617
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Intravenous Immunoglobulin (IVIG)
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">First-line treatment to reduce inflammation and risk of coronary artery complications.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/23283289" target="_blank">PMID:23283289</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Intravenous immunoglobulin (IVIG) and aspirin is the standard initial therapy in the treatment of Kawasaki disease."</div>
                
                
                <div class="evidence-explanation">The literature confirms that IVIG is part of the standard initial therapy for Kawasaki disease, aimed at reducing inflammation and preventing coronary artery complications.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38135926" target="_blank">PMID:38135926</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"For KD patients, male, children aged 3 to 9 years, and those with fever longer than 6 days before intravenous immunoglobulin (IVIG) use were more likely to have CAL."</div>
                
                
                <div class="evidence-explanation">The study discusses the use of IVIG and its timing in relation to the risk of coronary artery lesions, supporting its role in reducing such risks.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/24034380" target="_blank">PMID:24034380</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The standard of care for treatment is intravenous immunoglobulin plus aspirin, but adding corticosteroids may provide additional benefit for high-risk patients."</div>
                
                
                <div class="evidence-explanation">The literature states that IVIG is the standard of care for treating Kawasaki disease to reduce coronary artery complications.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Aspirin
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000181" target="_blank">
                            MAXO:0000181
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Used in high doses for its anti-inflammatory and antipyretic effects, followed by a lower dose to prevent blood clots.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/9513217" target="_blank">PMID:9513217</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Treatment includes the hospitalization of the child and subsequent administration of high doses of aspirin and intravenous immunoglobulin. With recovery, aspirin doses are reduced and the child may be monitored at home with outpatient follow-up."</div>
                
                
                <div class="evidence-explanation">This reference confirms that high doses of aspirin are used initially for Kawasaki disease, followed by lower doses after recovery.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/10935427" target="_blank">PMID:10935427</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Conventional therapy for KD includes intravenous gammaglobulin (2 g/kg as a single dose over 12 hours) and aspirin (acetylsalicylic acid; high dose until the fourteenth day of illness then low dose)."</div>
                
                
                <div class="evidence-explanation">This reference also supports the statement that high doses of aspirin are used initially, followed by lower doses.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32159800" target="_blank">PMID:32159800</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Low-dose aspirin plus IVIG might be as effective as high-dose aspirin plus IVIG for the initial treatment of Kawasaki disease. Considering that high-dose aspirin may cause more adverse reactions than low-dose aspirin, low-dose aspirin plus IVIG should be recommended as the first-line therapy in..."</div>
                
                
                <div class="evidence-explanation">This reference suggests that low-dose aspirin might be equally effective as high-dose aspirin and should be recommended to avoid adverse reactions, indicating a shift in treatment preference.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Corticosteroids
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Used in cases resistant to IVIG or with severe inflammation.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/31914832" target="_blank">PMID:31914832</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"We suggest using methylprednisolone pulse therapy as an alternative rescue therapy for immunoglobulin-resistant KD, as well as identifying high-risk patients who need initial corticosteroid with IVIG treatment with an adequate route, dose, and duration."</div>
                
                
                <div class="evidence-explanation">The literature supports the use of corticosteroids in cases of Kawasaki Disease that are resistant to IVIG or in high-risk patients with severe inflammation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/29101553" target="_blank">PMID:29101553</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"&#34;Resistant&#34; Kawasaki disease is defined by the American Heart Association as failure to respond within 36 h following the first dose of intravenous immunoglobulin. The optimal management of resistant Kawasaki disease remains uncertain, the outcomes are potentially serious, and the cost of some..."</div>
                
                
                <div class="evidence-explanation">This reference discusses the management of resistant Kawasaki Disease, which includes considering corticosteroid use.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/33541111" target="_blank">PMID:33541111</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"To prevent CAA, more intensified or adjunctive therapies using other agents, such as pulsed methylprednisolone, ciclosporin, infliximab, and Anakinra, should be considered for patients with these risk factors."</div>
                
                
                <div class="evidence-explanation">This reference mentions the use of pulsed methylprednisolone (a corticosteroid) for patients with Kawasaki Disease who are at risk of developing coronary artery abnormalities, indicating severe inflammation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">🔬</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    C-Reactive Protein (CRP)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Indicator of inflammation</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/34078404" target="_blank">PMID:34078404</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"CAL were found in 12.9 and 18.3% of the high and low CRP patients, respectively (p &lt; 0.001), based on z-scores; and in 9.9 and 12.5%, respectively (p = 0.001), based on the Japanese criteria in the acute phase."</div>
                
                
                <div class="evidence-explanation">The study indicates that CRP levels are elevated in Kawasaki Disease patients, with specific percentages of high and low CRP levels noted.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/39117827" target="_blank">PMID:39117827</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Kawasaki disease (KD) is a hyperinflammatory syndrome manifesting as an acute systemic vasculitis characterized by fever, nonsuppurative conjunctival injection, rash, oral mucositis, extremity changes, and cervical lymphadenopathy."</div>
                
                
                <div class="evidence-explanation">The abstract describes KD as a hyperinflammatory syndrome, implying elevated inflammatory markers such as CRP.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/37551875" target="_blank">PMID:37551875</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Complete blood count, C-reactive protein (CRP), liver and renal function tests, serum electrolytes, chest X-ray, NT-proBNP level, Bactec blood culture, urine microscopy and culture along with detailed physical examination was done for all cases and control."</div>
                
                
                <div class="evidence-explanation">The study includes CRP as part of the diagnostic tests for Kawasaki Disease, indicating its relevance as an inflammatory marker.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Erythrocyte Sedimentation Rate (ESR)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Indicator of inflammation</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/36604937" target="_blank">PMID:36604937</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"NLR &gt;/=2.08 was 82% sensitive and 80% specific in predicting CAL. ESR &gt;/=88 mm/h was 85% sensitive and 64% specific in predicting IVIg resistance."</div>
                
                
                <div class="evidence-explanation">The study indicates that ESR is elevated in Kawasaki Disease and can be used to predict IVIg resistance.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/33413220" target="_blank">PMID:33413220</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"In comparison between KDSS and TSS, patients with KDSS had a significantly higher erythrocyte sedimentation rate (ESR) and significantly lower creatinine."</div>
                
                
                <div class="evidence-explanation">The study shows that patients with Kawasaki Disease Shock Syndrome (KDSS) have significantly higher ESR levels.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/15677370" target="_blank">PMID:15677370</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The erythrocyte sedimentation rate (ESR) increased significantly 24 h after IVIG, and the elevated level was sustained for 7 days."</div>
                
                
                <div class="evidence-explanation">This reference shows that ESR levels are elevated during the acute stage of Kawasaki Disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Platelet Count
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Often seen in the subacute phase</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/33527178" target="_blank">PMID:33527178</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"In Kawasaki disease (KD), thrombocytosis is commonly found in the subacute phase."</div>
                
                
                <div class="evidence-explanation">The abstract states that thrombocytosis (elevated platelet count) is commonly found in the subacute phase of Kawasaki disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/6833960" target="_blank">PMID:6833960</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The second, subacute, phase begins with a decline of the acute findings and proceeds with desquamation of rash, joint manifestations, thrombocytosis, and cardiac disease."</div>
                
                
                <div class="evidence-explanation">The text explicitly mentions that thrombocytosis occurs during the subacute phase of Kawasaki disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Kawasaki Disease
description: Kawasaki Disease is a condition in children that involves inflammation
  of blood vessels throughout the body and is characterized by fever, rash, and other
  symptoms.
category: Pediatric Condition
parents:
- Vasculitis
prevalence:
- population: Children under 5
  percentage: Rare
  evidence:
  - reference: PMID:10392592
    supports: REFUTE
    snippet: Most children who contract this illness are less than two years old,
      and 80 percent of affected children are younger than five years of age.
    explanation: The statement that Kawasaki disease is rare in children under 5 is
      refuted by the literature, which indicates that 80% of affected children are
      younger than five years of age.
  - reference: PMID:36611091
    supports: REFUTE
    snippet: 83% of patients were &lt; 5 years of age and 10% were &lt; 6 months.
    explanation: The study shows that a significant proportion of Kawasaki disease
      cases occur in children under 5 years of age, refuting the statement that it
      is rare in this population.
progression:
- phase: Onset
  age_range: 6 months to 5 years
  notes: Sudden onset with high fever
  evidence:
  - reference: PMID:36472296
    supports: PARTIAL
    snippet: Given the variety and inconsistency of the clinical symptoms (the child
      had four of the five mandatory criteria together with prolonged fever), there
      was a late diagnosis, namely on day 10 of the disease.
    explanation: This reference mentions prolonged fever as a symptom of Kawasaki
      Disease but does not specify the sudden onset of high fever.
  - reference: PMID:34459958
    supports: PARTIAL
    snippet: A retrospective study that compared children younger than 6 months versus
      older children of a Spanish cohort of patients diagnosed with Kawasaki disease
      between 2011 and 2016 (Kawa-Race study).
    explanation: This reference provides information on Kawasaki Disease in children
      younger than 6 months and older but does not specifically mention the age range
      of 6 months to 5 years or the sudden onset with high fever.
  - reference: PMID:37553209
    supports: PARTIAL
    snippet: The mean age was 39.8 months (SD 37) and 592 (59%) were boys.
    explanation: This reference indicates that the mean age of Kawasaki Disease patients
      was within the 6 months to 5 years range but does not specifically mention the
      sudden onset with high fever.
  - reference: PMID:31910632
    supports: PARTIAL
    snippet: Kawasaki disease (KD) is the most frequent cause of coronary artery aneurysm
      (CAA) in children.
    explanation: This reference focuses on coronary artery aneurysm in children with
      Kawasaki Disease but does not provide specific details about the age range or
      the sudden onset with high fever.
  - reference: PMID:36611091
    supports: PARTIAL
    snippet: 83% of patients were &lt; 5 years of age and 10% were &lt; 6 months.
    explanation: This reference mentions that 83% of Kawasaki Disease patients were
      under 5 years of age but does not specify the sudden onset with high fever.
- phase: Acute
  duration: 1-2 weeks
  notes: High fever, rash, conjunctivitis, swollen hands and feet
  evidence:
  - reference: PMID:9665974
    supports: PARTIAL
    snippet: The illness is manifested by prolonged fever, conjunctival injection,
      enanthem, exanthem, erythema and swelling of the hands and feet, and cervical
      adenopathy. These acute features of illness are self-limiting.
    explanation: The reference confirms the symptoms mentioned in the statement (high
      fever, rash, conjunctivitis, swollen hands and feet) during the acute phase
      of Kawasaki Disease. However, it does not specify the exact duration of 1-2
      weeks.
  - reference: PMID:31974671
    supports: PARTIAL
    snippet: Arthritis in KD is usually non-erosive, self-limiting, and responds well
      to a short course of NSAIDs.
    explanation: The reference mentions that arthritis in KD is self-limiting, which
      implies a limited duration. However, it does not explicitly confirm the 1-2
      week duration for the acute phase.
  - reference: PMID:39117827
    supports: PARTIAL
    snippet: Kawasaki disease (KD) is a hyperinflammatory syndrome manifesting as
      an acute systemic vasculitis characterized by fever, nonsuppurative conjunctival
      injection, rash, oral mucositis, extremity changes, and cervical lymphadenopathy.
    explanation: The reference confirms the symptoms mentioned in the statement during
      the acute phase of Kawasaki Disease. However, it does not specify the exact
      duration of 1-2 weeks.
- phase: Subacute
  duration: 2-4 weeks
  notes: Peeling skin, joint pain, possible coronary artery changes
  evidence:
  - reference: PMID:28580712
    supports: PARTIAL
    snippet: Kawasaki disease begins as a necrotizing arteritis with neutrophilic
      infiltrate, followed by subacute/chronic changes and luminal myofibroblastic
      proliferation that can cause coronary artery stenosis.
    explanation: This reference mentions the subacute phase and coronary artery changes
      but does not specify the duration of 2-4 weeks or mention peeling skin and joint
      pain.
  - reference: PMID:33453126
    supports: PARTIAL
    snippet: All children with KD have fever accompanied by clinical signs, with four
      of the five classic criteria for complete KD being mucocutaneous, thus creating
      an important role for dermatologists.
    explanation: This reference discusses skin manifestations, which could include
      peeling, but does not specify the subacute phase duration or joint pain.
- phase: Convalescent
  duration: 6-8 weeks
  notes: Symptoms resolve, but coronary artery abnormalities may persist
  evidence:
  - reference: PMID:28580712
    supports: PARTIAL
    snippet: Kawasaki disease is an acute febrile arteritis of childhood that can
      result in coronary artery aneurysms if untreated in the first 10 and ideally
      7 days of illness. Kawasaki disease begins as a necrotizing arteritis with neutrophilic
      infiltrate, followed by subacute/chronic changes and luminal myofibroblastic
      proliferation that can cause coronary artery stenosis.
    explanation: The literature indicates that Kawasaki disease can lead to coronary
      artery abnormalities, but it does not specify that the convalescent phase lasts
      6-8 weeks. It supports the persistence of coronary artery abnormalities but
      does not confirm the exact duration of the convalescent phase.
  - reference: PMID:17033807
    supports: PARTIAL
    snippet: Conclusively, the most important predictor of CAA in KD is total duration
      of fever longer than 8 days. Early identification of IVGG non-responders and
      active therapeutic intervention for fever in KD cases might decrease the incidence
      of CAA.
    explanation: This reference discusses the importance of early intervention to
      prevent coronary artery abnormalities but does not provide specific information
      about the duration of the convalescent phase.
  - reference: PMID:29437127
    supports: NO_EVIDENCE
    snippet: Kawasaki Disease.
    explanation: This reference does not provide specific information about the duration
      of the convalescent phase or the persistence of coronary artery abnormalities.
pathophysiology:
- name: Vascular Inflammation
  description: Widespread inflammation of medium-sized arteries, including coronary
    arteries.
  downstream:
  - target: Aneurysm Formation
  evidence:
  - reference: PMID:23188196
    supports: SUPPORT
    snippet: Kawasaki disease (KD) is considered to be a kind of systemic vasculitis
      syndrome. It most frequently affects infants and young children and primarily
      invades medium-sized muscular arteries, including the coronary arteries.
    explanation: The literature confirms that Kawasaki disease involves widespread
      inflammation of medium-sized arteries, including coronary arteries.
  - reference: PMID:31599798
    supports: SUPPORT
    snippet: Kawasaki disease is a childhood vasculitis of unknown origin, whose major
      complication is the development of coronary artery aneurysms (CAA).
    explanation: The literature supports that Kawasaki disease leads to vascular inflammation
      and aneurysm formation.
  - reference: PMID:27090101
    supports: SUPPORT
    snippet: Coronary angiography showed multiple aneurysms which suggested sequelae
      of misdiagnosed Kawasaki disease.
    explanation: The case report indicates that Kawasaki disease can lead to aneurysm
      formation as a result of vascular inflammation.
  - reference: PMID:36102118
    supports: SUPPORT
    snippet: Long-term physiological dysfunction in coronary/systemic vasculature
      may persist in individuals with Kawasaki disease even in the absence of coronary
      artery abnormalities.
    explanation: The literature suggests long-term vascular dysfunction due to Kawasaki
      disease, supporting the idea of widespread vascular inflammation.
  - reference: PMID:35420684
    supports: SUPPORT
    snippet: Kawasaki disease, an acute febrile illness, can cause vasculitis in the
      coronary arteries.
    explanation: The literature confirms that Kawasaki disease causes inflammation
      in coronary arteries, leading to complications such as aneurysms.
  - reference: PMID:16990356
    supports: SUPPORT
    snippet: Kawasaki disease is an acute inflammatory syndrome that takes the form
      of systemic vasculitis, and predominantly affects children. Important complications
      of this disease are coronary artery dilation and aneurysm formation.
    explanation: The literature supports the statement that Kawasaki disease involves
      widespread vascular inflammation and aneurysm formation.
- name: Immune Response Dysregulation
  description: An abnormal immune response leading to vessel wall damage and inflammation.
  evidence:
  - reference: PMID:34890998
    supports: SUPPORT
    snippet: Increasing evidence shows that the pathogenesis of Kawasaki disease (KD)
      is caused by abnormal and unbalanced innate and adaptive immune responses.
    explanation: The literature supports the statement that Kawasaki Disease is characterized
      by immune response dysregulation leading to vessel wall damage and inflammation.
  - reference: PMID:30183655
    supports: SUPPORT
    snippet: Kawasaki disease (KD) is a vasculitis that is part of systemic vasculitis
      syndrome. It affects medium-sized vessels and is characterized by hypercytokinemia.
    explanation: This reference supports that KD involves immune dysregulation leading
      to vessel wall damage.
  - reference: PMID:30619331
    supports: SUPPORT
    snippet: Others have favored an autoreactive hypothesis that KD is triggered by
      an antigen that shares homology with structures in the vascular wall, and molecular
      mimicry resulting in an immune response directed to that tissue.
    explanation: This supports the notion of an abnormal immune response leading to
      vessel wall damage in KD.
  - reference: PMID:39117827
    supports: SUPPORT
    snippet: Kawasaki disease (KD) is a hyperinflammatory syndrome manifesting as
      an acute systemic vasculitis characterized by fever, nonsuppurative conjunctival
      injection, rash, oral mucositis, extremity changes, and cervical lymphadenopathy.
    explanation: This reference supports the statement by describing KD as a hyperinflammatory
      syndrome, which involves immune dysregulation.
phenotypes:
- category: Systemic
  name: Fever
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:30029859
    supports: SUPPORT
    snippet: Fever, abdominal pain, and vomiting were the most frequent symptoms observed
      and typical Kawasaki disease signs and symptoms appeared after intestinal complaints
      in all cases.
    explanation: The literature mentions fever as one of the most frequent symptoms
      observed in Kawasaki disease, supporting the statement that fever is a very
      frequent systemic diagnostic symptom of Kawasaki disease.
  - reference: PMID:31900257
    supports: SUPPORT
    snippet: The conundrum for acute paediatricians is which clinical features best
      distinguish the febrile child with possible KD, needing intravenous immunoglobulin,
      from the many other children with febrile illnesses.
    explanation: The literature highlights the challenge of distinguishing Kawasaki
      disease from other febrile illnesses, indicating that fever is a very frequent
      systemic diagnostic symptom in Kawasaki disease.
  - reference: PMID:26631821
    supports: SUPPORT
    snippet: The main symptoms were fever (100%), exanthema (98%), changes in the
      extremities (91%), conjunctivitis (77%), oral cavity changes (89%), cervical
      adenitis (55%) and cardiac abnormalities (45%).
    explanation: The literature states that fever is present in 100% of the cases,
      supporting the statement that fever is a very frequent systemic diagnostic symptom
      of Kawasaki disease.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
- category: Dermatologic
  name: Rash
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:26631821
    supports: SUPPORT
    snippet: The main symptoms were fever (100%), exanthema (98%)...
    explanation: Exanthema, which refers to a widespread rash, was present in 98%
      of the adult patients with Kawasaki Disease.
  - reference: PMID:1440951
    supports: SUPPORT
    snippet: We describe a four-year-old girl who presented with fever, a diffuse
      erythematous maculopapular rash...
    explanation: The case description includes a diffuse erythematous maculopapular
      rash as one of the clinical features.
  - reference: PMID:33453126
    supports: SUPPORT
    snippet: All children with KD have fever accompanied by clinical signs, with four
      of the five classic criteria for complete KD being mucocutaneous...
    explanation: The abstract emphasizes the mucocutaneous manifestations, which include
      skin rashes, as critical for diagnosing Kawasaki Disease.
  - reference: PMID:23481152
    supports: SUPPORT
    snippet: This is a report of a 4-year-old Hispanic boy who presented with skin
      changes to the lips and oral cavity, a generalized rash...
    explanation: The case report mentions a generalized rash as one of the symptoms
      of Kawasaki Disease.
  - reference: PMID:32843441
    supports: SUPPORT
    snippet: Both patients presented with fever lasting &gt;5 days and were found to
      have rash, conjunctival injection, and swollen lips.
    explanation: The patients with COVID-19 inflammatory syndrome had clinical features
      resembling Kawasaki Disease, including a rash.
  phenotype_term:
    preferred_term: Skin rash
    term:
      id: HP:0000988
      label: Skin rash
- category: Ocular
  name: Conjunctivitis
  frequency: VERY_FREQUENT
  notes: Non-purulent (no pus)
  evidence:
  - reference: PMID:34814144
    supports: SUPPORT
    snippet: In cross-sectional studies, KD was associated with allergic rhinitis
      (n = 6; OR, 1.69; 95% CI, 1.52-1.87), asthma (n = 3; OR, 1.72; 95% CI, 1.38-2.14),
      allergic conjunctivitis (n = 2; OR, 1.95; 95% CI, 1.68-2.27), and atopic dermatitis
      (n = 3; OR, 1.35; 95% CI, 1.22-1.49).
    explanation: The study shows that Kawasaki Disease is associated with allergic
      conjunctivitis, supporting the statement that conjunctivitis is very frequent
      in Kawasaki Disease.
  - reference: PMID:32843441
    supports: SUPPORT
    snippet: Both patients presented with fever lasting &gt;5 days and were found to
      have rash, conjunctival injection, and swollen lips.
    explanation: The description of conjunctival injection in patients with Kawasaki
      Disease supports the statement.
  - reference: PMID:7299613
    supports: SUPPORT
    snippet: In a prospective series, ophthalmologic examinations on 10 children with
      Kawasaki disease showed that eight had anterior uveitis during the acute phase
      of the illness.
    explanation: Although the study focuses on anterior uveitis, it indicates significant
      ocular involvement in Kawasaki Disease, supporting the statement indirectly.
  phenotype_term:
    preferred_term: Conjunctivitis
    term:
      id: HP:0000509
      label: Conjunctivitis
- category: Musculoskeletal
  name: Swelling of Hands and Feet
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:1704148
    supports: SUPPORT
    snippet: &#39;The six main clinical presentations of Kawasaki disease are: prolonged
      fever, conjunctivitis, lesions of the oral and pharyngeal mucosa, inflammatory
      reddening and swelling of the hands and feet, skin rash and cervical lymph node
      enlargement.&#39;
    explanation: The literature explicitly mentions that swelling of the hands and
      feet is one of the six main clinical presentations of Kawasaki disease.
  - reference: PMID:3333141
    supports: SUPPORT
    snippet: Early clinical features include fever, rash, conjunctival injection,
      dry reddened lips, oropharyngeal reddening, enlarged cervical nodes, and swelling
      and redness of hands and feet.
    explanation: The literature lists swelling and redness of hands and feet as early
      clinical features of Kawasaki disease.
- category: Dermatologic
  frequency: FREQUENT
  name: Peeling Skin
  notes: Particularly on the fingers and toes, often during the subacute phase
  evidence:
  - reference: PMID:6833960
    supports: SUPPORT
    snippet: The second, subacute, phase begins with a decline of the acute findings
      and proceeds with desquamation of rash...
    explanation: The term &#39;desquamation&#39; refers to peeling of the skin, which supports
      the statement that peeling skin is a frequent dermatologic manifestation of
      Kawasaki Disease, particularly during the subacute phase.
  - reference: PMID:3333141
    supports: SUPPORT
    snippet: Peeling of skin of fingers and toes, arthralgia, and marked thrombocytosis
      are frequent 1-2 weeks after onset.
    explanation: This reference explicitly mentions that peeling of the skin on the
      fingers and toes is a frequent occurrence 1-2 weeks after the onset of Kawasaki
      Disease.
  - reference: PMID:37065507
    supports: SUPPORT
    snippet: Kawasaki disease&#39;s clinical manifestations range from oral skin disease
      to the blistering of the mucosa, symptoms involving the hands and the feet,
      skin disease of the palms and soles, a desquamative rash...
    explanation: The term &#39;desquamative rash&#39; indicates peeling skin, supporting the
      statement that this is a frequent dermatologic manifestation of Kawasaki Disease.
- category: Oropharyngeal
  frequency: VERY_FREQUENT
  name: Red, Cracked Lips
  notes: Includes &#34;strawberry tongue&#34; and inflammation in the mouth and throat
  evidence:
  - reference: PMID:15835487
    supports: SUPPORT
    snippet: The disease can present with protean clinical manifestations which include
      high grade fever (for at least 5 days), rash, redness of the lips and a typical
      strawberry tongue, cervical lymph node enlargement (often unilateral), swelling
      over the hands/feet and, later a characteristic peripheral desquamation over
      the fingers and toes.
    explanation: The abstract mentions redness of the lips and a typical strawberry
      tongue as clinical manifestations of Kawasaki disease.
  - reference: PMID:30903929
    supports: SUPPORT
    snippet: Kawasaki disease (KD) is a febrile multisystemic vasculitis of unknown
      etiology whose coronary prognosis is improved by early diagnosis and management.
      ... ENT manifestations are frequently at the forefront of KD and constitute
      a misleading clinical picture responsible for delayed diagnosis and potentially
      inappropriate medico-surgical management.
    explanation: The study indicates that ENT (ear, nose, and throat) manifestations,
      which include oropharyngeal symptoms, are frequently at the forefront of KD.
  - reference: PMID:1440951
    supports: SUPPORT
    snippet: We describe a four-year-old girl who presented with fever, a diffuse
      erythematous maculopapular rash, bilateral nonpurulent bulbar conjunctivitis,
      dry, red, fissured lips, a tongue with a strawberry &#39;appearance&#39;, an erythematous
      pharynx, indurative erythema, and edema and desquamation of the face, hands
      and feet.
    explanation: The case description includes dry, red, fissured lips and a tongue
      with a strawberry &#39;appearance&#39;, supporting the statement.
  - reference: PMID:23481152
    supports: SUPPORT
    snippet: This is a report of a 4-year-old Hispanic boy who presented with skin
      changes to the lips and oral cavity, a generalized rash, edema of hands and
      feet, and peeling of the periungual areas of the fingers as well as to the groin
      and perianal areas.
    explanation: The report includes skin changes to the lips and oral cavity, which
      supports the statement.
- category: Cardiovascular
  frequency: OCCASIONAL
  name: Coronary Artery Aneurysms
  notes: Can lead to serious heart complications
  evidence:
  - reference: PMID:10512599
    supports: REFUTE
    snippet: Coronary artery aneurysms or ectasia develop in approximately 15-25%
      of children with the disease.
    explanation: The literature indicates that coronary artery aneurysms are a common
      complication of Kawasaki disease, occurring in 15-25% of cases, which is more
      frequent than &#39;occasional&#39;.
  - reference: PMID:31732547
    supports: REFUTE
    snippet: Twenty-three patients had SAAs, demonstrating an incidence of 14.2% (23
      of 162) in patients who were screened at 1 month after onset. The proportion
      of patients with SAAs was estimated to be 2% (23 of 1148) of all patients with
      KD.
    explanation: The incidence of coronary artery aneurysms (CAAs) in Kawasaki disease
      is significant, with a notable percentage of patients developing CAAs, indicating
      that the frequency is more than &#39;occasional&#39;.
  - reference: PMID:34651205
    supports: REFUTE
    snippet: Among the 640 KD children, most were 1-5 years old (415/640, 64.8%).
      Children &lt; 1 year old (31.6%) and &gt; 5 years old (28.3%) were more likely to
      have cardiovascular complications.
    explanation: The study shows a high incidence of cardiovascular complications
      in children with Kawasaki disease, indicating that coronary artery aneurysms
      and other heart complications are not just occasional.
  - reference: PMID:23075819
    supports: REFUTE
    snippet: Patients with persistent or remodeled coronary aneurysms after Kawasaki
      disease have a high rate of complications including thrombosis or stenosis leading
      to myocardial infarction.
    explanation: The literature indicates a high rate of complications from coronary
      artery aneurysms in Kawasaki disease, suggesting that these complications are
      not occasional but rather significant.
- category: Cardiovascular
  name: Aneurysm Formation
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Aneurysm Formation
    term:
      id: HP:0002617
      label: Vascular dilatation
biochemical:
- name: C-Reactive Protein (CRP)
  presence: Elevated
  context: Indicator of inflammation
  evidence:
  - reference: PMID:34078404
    supports: SUPPORT
    snippet: CAL were found in 12.9 and 18.3% of the high and low CRP patients, respectively
      (p &lt; 0.001), based on z-scores; and in 9.9 and 12.5%, respectively (p = 0.001),
      based on the Japanese criteria in the acute phase.
    explanation: The study indicates that CRP levels are elevated in Kawasaki Disease
      patients, with specific percentages of high and low CRP levels noted.
  - reference: PMID:39117827
    supports: SUPPORT
    snippet: Kawasaki disease (KD) is a hyperinflammatory syndrome manifesting as
      an acute systemic vasculitis characterized by fever, nonsuppurative conjunctival
      injection, rash, oral mucositis, extremity changes, and cervical lymphadenopathy.
    explanation: The abstract describes KD as a hyperinflammatory syndrome, implying
      elevated inflammatory markers such as CRP.
  - reference: PMID:37551875
    supports: SUPPORT
    snippet: Complete blood count, C-reactive protein (CRP), liver and renal function
      tests, serum electrolytes, chest X-ray, NT-proBNP level, Bactec blood culture,
      urine microscopy and culture along with detailed physical examination was done
      for all cases and control.
    explanation: The study includes CRP as part of the diagnostic tests for Kawasaki
      Disease, indicating its relevance as an inflammatory marker.
  - reference: PMID:34731266
    supports: SUPPORT
    snippet: The KD group had a significantly higher level of initial c-reactive protein
      (CRP) compared to the BI and NBI groups, with a cutoff value of 4.85 mg/dL in
      comparison with the BI group and 3.32 mg/dL in comparison with the NBI group.
    explanation: The study provides specific CRP levels that are elevated in Kawasaki
      Disease compared to bacterial and non-bacterial infections.
- name: Erythrocyte Sedimentation Rate (ESR)
  presence: Elevated
  context: Indicator of inflammation
  evidence:
  - reference: PMID:36604937
    supports: SUPPORT
    snippet: NLR &gt;/=2.08 was 82% sensitive and 80% specific in predicting CAL. ESR
      &gt;/=88 mm/h was 85% sensitive and 64% specific in predicting IVIg resistance.
    explanation: The study indicates that ESR is elevated in Kawasaki Disease and
      can be used to predict IVIg resistance.
  - reference: PMID:33413220
    supports: SUPPORT
    snippet: In comparison between KDSS and TSS, patients with KDSS had a significantly
      higher erythrocyte sedimentation rate (ESR) and significantly lower creatinine.
    explanation: The study shows that patients with Kawasaki Disease Shock Syndrome
      (KDSS) have significantly higher ESR levels.
  - reference: PMID:15677370
    supports: SUPPORT
    snippet: The erythrocyte sedimentation rate (ESR) increased significantly 24 h
      after IVIG, and the elevated level was sustained for 7 days.
    explanation: This reference shows that ESR levels are elevated during the acute
      stage of Kawasaki Disease.
- name: Platelet Count
  presence: Elevated
  context: Often seen in the subacute phase
  evidence:
  - reference: PMID:33527178
    supports: SUPPORT
    snippet: In Kawasaki disease (KD), thrombocytosis is commonly found in the subacute
      phase.
    explanation: The abstract states that thrombocytosis (elevated platelet count)
      is commonly found in the subacute phase of Kawasaki disease.
  - reference: PMID:6833960
    supports: SUPPORT
    snippet: The second, subacute, phase begins with a decline of the acute findings
      and proceeds with desquamation of rash, joint manifestations, thrombocytosis,
      and cardiac disease.
    explanation: The text explicitly mentions that thrombocytosis occurs during the
      subacute phase of Kawasaki disease.
diagnosis:
- name: Echocardiogram
  notes: Used to check for coronary artery involvement
  evidence:
  - reference: PMID:28921836
    supports: SUPPORT
    snippet: Echocardiography is an excellent noninvasive imaging modality for evaluation
      and follow-up of cardiac lesions, especially coronary artery changes occurring
      as a result of Kawasaki disease.
    explanation: The reference clearly states that echocardiography is used to evaluate
      coronary artery changes in Kawasaki disease, supporting the statement.
- name: Blood Tests
  notes: Elevated inflammatory markers (CRP and ESR)
  evidence:
  - reference: PMID:36569014
    supports: PARTIAL
    snippet: Since KD is a disease caused by arterial inflammation, many patients
      with KD have elevated levels of inflammatory biomarkers, such as C-reactive
      protein (CRP), erythrocyte sedimentation rate (ESR), and serum amyloid A protein
      (SAA) in blood tests.
    explanation: The literature suggests that many patients with Kawasaki Disease
      have elevated inflammatory markers, but it also reports cases where such elevations
      are not observed.
  - reference: PMID:34854940
    supports: SUPPORT
    snippet: Thrombocytosis, conjunctivitis, and oral and/or pharyngeal erythema and/or
      strawberry tongue were associated with higher rates of echocardiographic abnormalities.
    explanation: The study indicates that inflammatory markers are associated with
      echocardiographic abnormalities in Kawasaki Disease, supporting the statement.
  - reference: PMID:33481812
    supports: SUPPORT
    snippet: We obtained eight independent predictors (platelets, eosinophil, alanine
      aminotransferase, C-reactive protein, hemoglobin, mean corpuscular hemoglobin,
      mean corpuscular hemoglobin concentration, and monocyte).
    explanation: CRP is identified as one of the independent predictors for Kawasaki
      Disease, supporting the statement.
  - reference: PMID:27881022
    supports: SUPPORT
    snippet: YKL-40 concentration in the serum of KD patients significantly increased
      during the acute disease phase compared with those of disease controls and healthy
      controls.
    explanation: The study supports the presence of elevated inflammatory markers
      in Kawasaki Disease patients.
  - reference: PMID:37188888
    supports: SUPPORT
    snippet: PK2 can significantly predict Kawasaki disease independently of CRP and
      ESR (p &lt; 0.0001).
    explanation: CRP and ESR are mentioned as markers that can independently predict
      Kawasaki Disease, supporting the statement.
treatments:
- name: Intravenous Immunoglobulin (IVIG)
  description: First-line treatment to reduce inflammation and risk of coronary artery
    complications.
  evidence:
  - reference: PMID:23283289
    supports: SUPPORT
    snippet: Intravenous immunoglobulin (IVIG) and aspirin is the standard initial
      therapy in the treatment of Kawasaki disease.
    explanation: The literature confirms that IVIG is part of the standard initial
      therapy for Kawasaki disease, aimed at reducing inflammation and preventing
      coronary artery complications.
  - reference: PMID:38135926
    supports: SUPPORT
    snippet: For KD patients, male, children aged 3 to 9 years, and those with fever
      longer than 6 days before intravenous immunoglobulin (IVIG) use were more likely
      to have CAL.
    explanation: The study discusses the use of IVIG and its timing in relation to
      the risk of coronary artery lesions, supporting its role in reducing such risks.
  - reference: PMID:24034380
    supports: SUPPORT
    snippet: The standard of care for treatment is intravenous immunoglobulin plus
      aspirin, but adding corticosteroids may provide additional benefit for high-risk
      patients.
    explanation: The literature states that IVIG is the standard of care for treating
      Kawasaki disease to reduce coronary artery complications.
  - reference: PMID:34535199
    supports: SUPPORT
    snippet: Intravenous immunoglobulin (IVIG) has become an effective treatment regimen,
      which can effectively reduce the incidence of cardiovascular complications.
    explanation: The literature confirms that IVIG is effective in reducing cardiovascular
      complications in Kawasaki disease.
  - reference: PMID:32888683
    supports: SUPPORT
    snippet: Treatment of Kawasaki disease (KD) with intravenous immunoglobulin (IVIG)
      administered within the initial 10 days of fever onset decreases the risk of
      coronary artery aneurysms (CAAs) from ∼ 25% to less than 5%.
    explanation: The literature provides evidence that IVIG significantly reduces
      the risk of coronary artery complications when administered early.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Aspirin
  description: Used in high doses for its anti-inflammatory and antipyretic effects,
    followed by a lower dose to prevent blood clots.
  evidence:
  - reference: PMID:9513217
    supports: SUPPORT
    snippet: Treatment includes the hospitalization of the child and subsequent administration
      of high doses of aspirin and intravenous immunoglobulin. With recovery, aspirin
      doses are reduced and the child may be monitored at home with outpatient follow-up.
    explanation: This reference confirms that high doses of aspirin are used initially
      for Kawasaki disease, followed by lower doses after recovery.
  - reference: PMID:10935427
    supports: SUPPORT
    snippet: Conventional therapy for KD includes intravenous gammaglobulin (2 g/kg
      as a single dose over 12 hours) and aspirin (acetylsalicylic acid; high dose
      until the fourteenth day of illness then low dose).
    explanation: This reference also supports the statement that high doses of aspirin
      are used initially, followed by lower doses.
  - reference: PMID:32159800
    supports: PARTIAL
    snippet: Low-dose aspirin plus IVIG might be as effective as high-dose aspirin
      plus IVIG for the initial treatment of Kawasaki disease. Considering that high-dose
      aspirin may cause more adverse reactions than low-dose aspirin, low-dose aspirin
      plus IVIG should be recommended as the first-line therapy in the initial treatment
      of Kawasaki disease.
    explanation: This reference suggests that low-dose aspirin might be equally effective
      as high-dose aspirin and should be recommended to avoid adverse reactions, indicating
      a shift in treatment preference.
  - reference: PMID:28043685
    supports: PARTIAL
    snippet: The use of medium- or higher-dose ASA in acute Kawasaki disease did not
      prevent CAA. A future randomized controlled trial is needed to determine the
      optimum dose of ASA.
    explanation: This reference indicates that higher doses of aspirin did not prevent
      coronary artery aneurysms and suggests the need for further research to determine
      the optimal dose.
  treatment_term:
    preferred_term: cardiovascular agent therapy
    term:
      id: MAXO:0000181
      label: cardiovascular agent therapy
- name: Corticosteroids
  description: Used in cases resistant to IVIG or with severe inflammation.
  evidence:
  - reference: PMID:31914832
    supports: SUPPORT
    snippet: We suggest using methylprednisolone pulse therapy as an alternative rescue
      therapy for immunoglobulin-resistant KD, as well as identifying high-risk patients
      who need initial corticosteroid with IVIG treatment with an adequate route,
      dose, and duration.
    explanation: The literature supports the use of corticosteroids in cases of Kawasaki
      Disease that are resistant to IVIG or in high-risk patients with severe inflammation.
  - reference: PMID:29101553
    supports: SUPPORT
    snippet: &#39;&#34;Resistant&#34; Kawasaki disease is defined by the American Heart Association
      as failure to respond within 36 h following the first dose of intravenous immunoglobulin.
      The optimal management of resistant Kawasaki disease remains uncertain, the
      outcomes are potentially serious, and the cost of some treatments is considerable.&#39;
    explanation: This reference discusses the management of resistant Kawasaki Disease,
      which includes considering corticosteroid use.
  - reference: PMID:33541111
    supports: SUPPORT
    snippet: To prevent CAA, more intensified or adjunctive therapies using other
      agents, such as pulsed methylprednisolone, ciclosporin, infliximab, and Anakinra,
      should be considered for patients with these risk factors.
    explanation: This reference mentions the use of pulsed methylprednisolone (a corticosteroid)
      for patients with Kawasaki Disease who are at risk of developing coronary artery
      abnormalities, indicating severe inflammation.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
notes: Prompt treatment is crucial to prevent coronary artery complications. Long-term
  follow-up may be necessary for some patients.
disease_term:
  preferred_term: Kawasaki disease
  term:
    id: MONDO:0012727
    label: mucocutaneous lymph node syndrome
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Kawasaki_Disease.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>